Twist Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Twist Bioscience 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TWST

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. 

CEO
Emily Marine Leproust
CEOEmily Marine Leproust
Employees
979
Employees979
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
979
Employees979

TWST Key Statistics

Market cap
2.88B
Market cap2.88B
Price-Earnings ratio
-36.81
Price-Earnings ratio-36.81
Dividend yield
Dividend yield
Average volume
1.37M
Average volume1.37M
High today
$48.11
High today$48.11
Low today
$46.06
Low today$46.06
Open price
$47.47
Open price$47.47
Volume
747.33K
Volume747.33K
52 Week high
$57.88
52 Week high$57.88
52 Week low
$23.30
52 Week low$23.30

Stock Snapshot

With a market cap of 2.88B, Twist Bioscience(TWST) trades at $46.92. The stock has a price-to-earnings ratio of -36.81.

As of 2026-03-01, Twist Bioscience(TWST) stock has fluctuated between $46.06 and $48.11. The current price stands at $46.92, placing the stock +1.9% above today's low and -2.5% off the high.

Twist Bioscience(TWST) shares are trading with a volume of 747.33K, against a daily average of 1.37M.

During the past year, Twist Bioscience(TWST) stock moved between $23.30 at its lowest and $57.88 at its peak.

During the past year, Twist Bioscience(TWST) stock moved between $23.30 at its lowest and $57.88 at its peak.

TWST News

Simply Wall St 1d
Assessing Twist Bioscience Valuation After New Invenra Bispecific Antibody Licensing Deal

Twist Bioscience (TWST) is back in focus after announcing a licensing deal with Invenra that brings the B-Body bispecific antibody platform under a co-exclusive...

Assessing Twist Bioscience Valuation After New Invenra Bispecific Antibody Licensing Deal
Simply Wall St 2d
Is Twist Bioscience Using Invenra Deal To Quietly Redefine Its Biologics Platform Strategy?

In February 2026, Twist Bioscience Corporation announced it had entered a licensing agreement with Invenra Inc., becoming co-exclusive provider of Invenra’s B-B...

Is Twist Bioscience Using Invenra Deal To Quietly Redefine Its Biologics Platform Strategy?
Simply Wall St 4d
Twist Bioscience Expands Antibody Discovery With Invenra Bispecific Platform Deal

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal e...

Twist Bioscience Expands Antibody Discovery With Invenra Bispecific Platform Deal

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

People also own

Based on the portfolios of people who own TWST. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.